Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day PodcastNewsfile Corp • 05/07/21
Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip VideoNewsfile Corp • 04/27/21
Lexaria Bioscience says dosing in first human trial of DehydraTECH CBD to treat high blood pressure has startedProactive Investors • 04/22/21
Lexaria Bioscience says DehyrdaTECH CBD client's product featured in New Hope Network best of 2020 listProactive Investors • 04/14/21
Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope NetworkAccesswire • 04/14/21
Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion MarketplaceNewsfile Corp • 04/08/21
Lexaria technology generates positive stability testing for ready-to-drink CBD beveragesProactive Investors • 03/24/21
Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD BeveragesAccesswire • 03/24/21
Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D programProactive Investors • 03/16/21
Lexaria Bioscience updates on progress of its DehydraTECH CBD studies to treat high blood pressureProactive Investors • 03/15/21
Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021Accesswire • 03/11/21
Lexaria Bioscience's DehydraTECH drug delivery system can unlock more effective CBD — and may even help fight COVID-19Proactive Investors • 03/02/21
Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infectionPRNewsWire • 02/16/21
Lexaria Bioscience expands DehydraTECH CBD hypertension program with two new human trials; updates for othersProactive Investors • 02/11/21